Results 121 to 130 of about 13,664 (205)

Critical appraisal of the role of recombinant activated factor VII in the treatment of hemophilia patients with inhibitors

Journal of Blood Medicine, 2010
Ampaiwan Chuansumrit1, Pantep Angchaisuksiri2, Nongnuch Sirachainan11Departments of Pediatrics and 2Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University,  Bangkok, ThailandAbstract: Hemophilia patients with inhibitors faced ...
Ampaiwan Chuansumrit, Pantep Angchaisuksiri, Nongnuch Sirachainan   +2 more
doaj  

Mode of action of recombinant factor VIIa and the use in severe haemorrhage states

Zdravniški Vestnik, 2006
Background: Diffuse non-surgical life threatening haemorrhages are common cause of death in surgical patients. They are usually caused by a disorder of haemostasis of different aetiologies.
Adela Stecher, Boriana Kremžar
doaj  

Life-Threatening Pulmonary Hemorrhage Responds to Recombinant Factor VIIa: A Case Series in South Florida Hospitals. [PDF]

Cureus, 2019
Diaz R, Almeida P, Alvarez M, Ferrer G, Hernandez F.   +4 more
europepmc   +1 more source

Correction to: Lessons from a systematic literature review of the effectiveness of recombinant factor VIIa in acquired haemophilia. [PDF]

Ann Hematol, 2018
Tiede A, Worster A.
europepmc   +1 more source

Recombinant Factor VIIa Prophylaxis in 2 Brothers with Bernard-Soulier Syndrome. [PDF]

Am J Case Rep
Almatar E, Alsharidah S, Hashem OA.
europepmc   +1 more source

Efficacy and Safety Analyses of Recombinant Factor VIIa in Severe Post-Partum Hemorrhage. [PDF]

J Clin Med
Caram-Deelder C, McKinnon Edwards H, Zdanowicz JA, van den Akker T, Birkegård C, Blatný J, van der Bom JG, Colucci G, van Duuren D, van Geloven N, Henriquez DDCA, Knight M, Korsholm L, Landorph A, Lavigne Lissalde G, McQuilten ZK, Surbek D, Wellard C, Wood EM, Mercier FJ.   +19 more
europepmc   +1 more source

Lessons from a systematic literature review of the effectiveness of recombinant factor VIIa in acquired haemophilia. [PDF]

Ann Hematol, 2018
Tiede A, Worster A.
europepmc   +1 more source

The anticoagulant effects of milvexian, a novel small molecule factor XIa inhibitor, are neutralized by activated prothrombin complex concentrates and recombinant factor VIIa in human plasma and whole blood in vitro. [PDF]

Res Pract Thromb Haemost
Bunce M, Huang Devine Z, Chintala M.
europepmc   +1 more source

Recombinant Factor VIIa Use for Endoscopic Retrograde Cholangiopancreatography With Sphincterotomy in a Patient With Choledocholithiasis and Unusual Coagulopathy. [PDF]

Gastroenterology Res, 2017
Abdulsamad M, Reddy P, Guvvala S, Dev A.
europepmc   +1 more source

Recombinant factor VIIa use in patients presenting with intracranial hemorrhage. [PDF]

Springerplus, 2014
Yampolsky N, Stofko D, Veznedaroglu E, Liebman K, Binning MJ.   +4 more
europepmc   +1 more source